Payment for Cancer Biomarker Testing
"At a time when payers, struggling to thrive in the current
dynamic health care environment, must clearly understand
the cost of patient care,3 they ‘‘are definitely on board with
biomarker tests, particularly when it means that they are
paying for drugs that patients will likely respond to—and
conversely are not paying for several months of drugs or
chemotherapy that will have little positive effect.’’ 8 But it
has been difficult to ‘‘get a handle’’ on biomarker test
payment because payment requirements evolve and change
over time, payers approach payment in different ways for
different technologies,9 and the majority of payers pay for
diagnostic molecular tests separately from the associated
therapy.10 In fact, payment for cancer biomarker tests may
be a more difficult issue than payment for new oncology
treatments themselves."
No comments:
Post a Comment